All News

The PD-1 inhibitor was approved along with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, and is indicated for patients who progressed on or after platinum-containing chemotherapy or EGFR- or ALK-targeted agents in patients harboring those mutations.

Every October, pink ribbons appear to signal the start of Breast Cancer Awareness Month. Pink has become the color of breast cancer, but some survivors don't like the color pink and they have a good reason for feeling the way they do.

From the time my wife was diagnosed, people asked if she smoked. If the answer was yes, would that make it OK that she was sick?

It's all about having a plan. Plans give hope. Plans inspire.

The combination was approved for patients with BRAF V600 wild-type unresectable or metastatic melanoma, based on results from a phase 2 study.

Cancer is an emotional challenge all by itself. Curiously enough, a cancer diagnosis gave me a new lease on my emotional life. But sometimes a person with the best of intentions will falter. Knowing when to seek help can save a life.

The stage 4 lung cancer life twists and turns down a bumpy road, but it is a road that I am lucky enough to still be traveling.

An easy-to-use list to stay calm when the cancer panic hits.

To gain a patient's perspective on the Genomics of Young Lung Cancer Study and the importance of genomic testing, we spoke with Corey Wood, a 23-year-old trial participant and lung cancer survivor.

Two-time cancer survivor struggles living with chemo brain.

The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center.

No doubt, dealing with cancer can be overwhelming. Learn 24 tips to find levels of comfort during cancer and support healing in the process.

In many cases, losing your hair is part of cancer treatment and it can be very emotional. For me, it symbolized so much more than just a physical change.

All of us who are called up to the frontlines of the cancer battlefield know that, much like today's military, tours of duty are not set in stone.

The approval was based on results from the phase 3 RECOURSE trial.

This is how my family and I were thrown into the cancer world.

Differing opinions on follow-up protocols can make it hard to advocate for oneself and to advise others.

Marianne Davies, from Smilow Cancer Hospital, Yale School of Nursing, provides an overview of immunotherapy-related side effects that patient with lung cancer may experience.

Kevin gives advice for giving advice.

At an 18-month analysis, the overall survival rate with the PD-1 inhibitor was 28 percent versus 13 percent with docetaxel in previously treated patients with squamous NSCLC.

The study was a secondary analysis of the PREDIMED trial, which involved 4,282 women in Spain aged 60 to 80 and at high risk of cardiovascular disease.

Researchers at UAB found that patients aged younger than 65 who were unmarried, lived in lower-income areas, and who were uninsured or Medicaid beneficiaries were at significantly higher risk of premature mortality.

The approval of Varubi was based on data from several phase 3 trials of the agent in more than 2,500 patients receiving various emetogenic chemotherapy agents.

Linda R. Duska, gynecologic oncologist, University of Virginia, discusses the Foundation for Women's Cancer.

Electroacupuncture produced larger placebo and smaller nocebo effects than did gabapentin for treating hot flashes among breast cancer survivors.

The breakthrough therapy designation will expedite the development and review of Opdivo in advanced renal cell carcinoma.

This reanalysis confirmed that there is no difference for a radiotherapy-first versus a chemotherapy-first strategy in this setting, but there is a major difference in long-term outcomes for molecular stratification independent of treatment.

These data were presented in late May at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology professionals in Chicago.